CLINICAL_TRIALS
trial_result
· 2015-08-28
Clinical Trial Update: Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation [Phase 2]
Summary
Phase 2 study of VX-809 (lumacaftor) in cystic fibrosis patients with the ∆F508 mutation completed, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2015-08-28